CTOs on the Move

Columbus Regional Healthcare System

www.crhs.net

 
As the region`s leading provider of health care, Columbus Regional Health has touched the lives of most of the children and adults in this region through its comprehensive network of services.   Located in the West Georgia city of Columbus, Columbus Regional Health was established in 1986 as a not-for-profit health services organization, but its roots can be traced back to 1836 when the local hospital was a small wooden building on the banks of the Chattahoochee River.
  • Number of Employees: 10K-50K
  • Annual Revenue: $500M-1 Billion
  • www.crhs.net
  • 710 Center St
    Columbus, GA USA 31901
  • Phone: 706.571.1000

Executives

Name Title Contact Details

Similar Companies

Train for Compliance

Train for Compliance is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CMC ICOS Biologics Inc.

CMC ICOS Biologics Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Bothell, WA. To find more information about CMC ICOS Biologics Inc., please visit www.cmcbio.com

Houston Foam Plastics Inc

Houston Foam Plastics Inc is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

QueensCare Family Clinics

QueensCare Family Clinics is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. QueensCare Family Clinics is based in Los Angeles, CA. You can find more information on QueensCare Family Clinics at www.queenscare.org

Clarvista Medical

ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.